{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:56:51Z","timestamp":1777417011646,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe a case of a child with altered mental status following the topical administration of doxepin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A five-year-old Hispanic girl was brought to the emergency department because she was difficult to arouse at school. She had recently developed a generalized eczematous rash for which she was prescribed doxepin hydrochloride 5% cream. An entire tube (30 g) of doxepin cream was applied in the 24 hours prior to presentation. The patient was responsive only to noxious stimuli, with no focal neurologic abnormalities. She was decontaminated and observed in a pediatric intensive care unit. By 18 hours after presentation, she had fully recovered and was discharged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Topical doxepin, available as a 5% cream, is indicated for the treatment of pruritus secondary to eczematous dermatoses in adults. Diminished skin integrity and the application of a massive quantity of doxepin 5% cream to a large body surface area contributed to the toxicity in this child. Since the safety and efficacy of doxepin cream has not been established in children younger than 12 years, it should be used with caution in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.19170","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T16:37:47Z","timestamp":1054658267000},"page":"328-329","source":"Crossref","is-referenced-by-count":26,"title":["Doxepin Toxicity in a Child following Topical Administration"],"prefix":"10.1177","volume":"34","author":[{"given":"Michele","family":"Zell-Kanter","sequence":"first","affiliation":[{"name":"Michele Zell-Kanter PharmD, Coordinator, Toxikon Consortium, Division of Occupational Medicine, Cook County Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore S","family":"Toerne","sequence":"additional","affiliation":[{"name":"Theodore S Toerne MD, Assistant Professor and Consulting Medical Toxicologist, Department of Emergency Medicine, University of Mississippi Medical Center, Mississippi Poison Center, Jackson, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Katharina Spiegel PhD, Manager, Keck Biophysics Facility, Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Negrusz","sequence":"additional","affiliation":[{"name":"Adam Negrusz PhD, Assistant Professor of Forensic Sciences, Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,3,1]]},"reference":[{"key":"bibr1-aph.19170","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70225-X"},{"key":"bibr2-aph.19170","first-page":"205","volume-title":"Discoveries in biological psychiatry","author":"Kuhn R","year":"1970"},{"key":"bibr3-aph.19170","first-page":"582","volume":"58","author":"Richelson E","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"bibr4-aph.19170","first-page":"99","volume":"36","year":"1994","journal-title":"Med Lett Drugs Ther"},{"key":"bibr5-aph.19170","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690240133033"},{"key":"bibr6-aph.19170","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03743.x"},{"key":"bibr7-aph.19170","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr8-aph.19170","unstructured":"McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997:2746\u20137."},{"key":"bibr9-aph.19170","first-page":"685","volume-title":"Pediatric dermatology","author":"Krafchick BR","year":"1995"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:03:10Z","timestamp":1777374190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.19170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1345\/aph.19170"],"URL":"https:\/\/doi.org\/10.1345\/aph.19170","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}